移植骨髓间充质干细胞预防野百合碱诱导的肺动脉高压(英文)

Bone marrow mesenchymal stem cells against monocrotaline-induced pulmonary artery hypertension

背景:干细胞移植治疗肺动脉高压有一定疗效。目的:观察骨髓间充质干细胞移植治疗肺动脉高压的效果及并探讨其作用机制。方法:采用密度梯度离心法体外培养、纯化、扩增获得大鼠骨髓间充质干细胞,经荧光染料标记后备用。大鼠皮下注射野百合碱建立肺动脉高压模型,建模后1周将大鼠随机分为3组,干细胞移植组和肺动脉高压组大鼠皮下注射野百合碱建立肺动脉高压模型,1周后干细胞组大鼠经舌下静脉注射骨髓间充质干细胞悬液,肺动脉高压组注射等量不含干细胞的培养液,对照组皮下注射等量生理盐水。结果与结论:移植后2周,与野百合碱诱导的肺动脉高压大鼠相比干细胞移植组血流动力学参数及右心室与体质量之比明显改善(P<0.05);肺血管重构程度减轻(P<0.05)。荧光显微镜下发现干细胞组移植的骨髓间充质干细胞在大鼠体内能存活至少2周,部分干细胞能转化为血管平滑肌细胞。说明静脉移植骨髓间充质干细胞能明显改善野百合碱造成的肺动脉高压大鼠肺血管和右心室结构的损伤。

BACKGROUND： Stem cell transplantation has a certain effect in the treatment pulmonary arterial hypertension. OBJECTIVE： To investigate the effect of bone marrow mesenchymal stem cells transplantation on the treatment of pulmonary arterial hypertension and to discuss the mechanism. METHODS： Bone marrow mesenchymal stem cells were in vitro cultured, purified and amplified by density gradient centrifugation method, and labeled with the fluorescent dye for preparation. Pulmonary arterial hypertension model was established by subcutaneous injection of monocrotaline. One week after modeling, the rats were randomly divided into three groups. Rats in the stem cell transplantation group and pulmonary arterial hypertension group received subcutaneous injection of monocrotaline to establish the pulmonary arterial hypertension model. One week later, the rats in the stem cell transplantation group received sublingual vein injection of bone marrow mesenchymal stem cell solution, the rats in the pulmonary arterial hypertension group were injected with the culture medium without stem cells, and the rats in the control group were injected with the normal saline in the same dose. RESULTS AND CONCLUSION： At 2 weeks after transplantation, compared with the mesanchymal-induced pulmonary arterial hypertension rats, the hemodynamic parameters and the ratio of right ventricular/body weight of the rats in the stem cell transplantation group were significantly improved （P 〈 0.05）; the degree of pulmonary vascular remodeling was significantly reduced （P 〈 0.05）. Fluorescence microscope observation showed that the transplanted bone marrow mesenchymal stem cells could alive at least 2 weeks in the stem cell transplantation group, and part of the stem cells could differentiate into pulmonary vascular endothelial cells.. The results show that bone marrow mesenchymal stem cell transplantation can significantly improve the pulmonary vascular and right ventricular structural impairments in the rats with mesenchymal-induced pulmonary arterial hypertension.